IgA nephropathy, also known as Berger’s disease, is a rare kidney disorder characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, leading to inflammation and potential decline in kidney function. Given the increasing prevalence of this condition, recent research has focused on identifying effective treatment options. One promising development comes from the interim results of the APPLAUSE-IgAN study, which investigates the efficacy of iptacopan, a novel complement inhibitor, in patients with this challenging disease.
The APPLAUSE-IgAN study is a phase III clinical trial that aims to assess the safety and efficacy of iptacopan, also branded as Fabhalta, compared to a placebo in adults diagnosed with IgA nephropathy. In the initial randomization phase, 250 patients were analyzed, with a healthy mix of demographics consisting of approximately 47.6% women and a significant proportion (51.2%) hailing from Asia. This was a pivotal analysis that paved the way toward regulatory scrutiny and eventual FDA approval anticipated in August 2024.
Patients were administered iptacopan at a dose of 200 mg or a placebo twice daily over a planned treatment period of 24 months. The goal was to observe changes in the urinary protein-to-creatinine ratio (UPCR) as a primary endpoint, which indicates the degree of proteinuria and serves as a vital marker for kidney function.
The results presented by Dr. Dana V. Rizk at the American Society of Nephrology Kidney Week indicated a statistically significant reduction in UPCR levels in participants receiving iptacopan compared to those on placebo. By the end of month nine, there was a notable reduction of 38.3% (P
Leave a Reply